Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis

DOI: https://doi.org/10.1177/24755303231195868

Abstract:[This corrects the article DOI: 10.1177/24755303211051724.].

What problem does this paper attempt to address?

Corrigendum: IL36G is associated with cutaneous antiviral competence in psoriasis

You-Wang Lu,Yong-Jun Chen,Nian Shi,Lu-Hui Yang,Hong-Mei Wang,Rong-Jing Dong,Yi-Qun Kuang,Yu-Ye Li

DOI: https://doi.org/10.3389/fimmu.2022.1043240

IF: 7.3

2022-10-17

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.971071.].

immunology
Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab

DOI: https://doi.org/10.1177/24755303231195884

Abstract:[This corrects the article DOI: 10.1177/24755303211029598.].
Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series

DOI: https://doi.org/10.1177/24755303231195862

Abstract:[This corrects the article DOI: 10.1177/2475530320970538.].
Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

DOI: https://doi.org/10.1177/24755303231195874

Abstract:[This corrects the article DOI: 10.1177/24755303211056059.].
Corrigendum to “Exploring comorbidity and pharmacological treatment patterns in psoriasis - A retrospective population-based cross-sectional study”

DOI: https://doi.org/10.1177/26335565231223601

2023-12-01

Journal of Multimorbidity and Comorbidity

Abstract:[This corrects the article DOI: 10.1177/26335565231212336.].
Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

DOI: https://doi.org/10.1177/24755303231195882

Abstract:[This corrects the article DOI: 10.1177/24755303221077211.].
Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

DOI: https://doi.org/10.1177/24755303231195864

Abstract:[This corrects the article DOI: 10.1177/2475530320925067.].
Corrigendum to Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey

DOI: https://doi.org/10.1177/24755303231195873

Abstract:[This corrects the article DOI: 10.1177/24755303211067822.].
Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis

DOI: https://doi.org/10.1177/24755303231195863

Abstract:[This corrects the article DOI: 10.1177/2475530320970530.].
Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series

DOI: https://doi.org/10.1177/24755303231195857

Abstract:[This corrects the article DOI: 10.1177/2475530321995516.].
Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities

DOI: https://doi.org/10.1177/24755303231195867

Abstract:[This corrects the article DOI: 10.1177/24755303221131257.].
Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes & Diseases 9(2022) 443–455]

Xiaohua Shen,Chunhua Weng,Yucheng Wang,Cuili Wang,Feng Shi,Xiayu Li,Heng Li,Hong Jiang,Haibing Wang,Jianghua Chen

DOI: https://doi.org/10.1016/j.gendis.2022.03.001

IF: 7.376

2022-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2020.07.005.][This corrects the article DOI: 10.1016/j.gendis.2021.09.001.].
Corrigendum to Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options

DOI: https://doi.org/10.1177/24755303231195875

Abstract:[This corrects the article DOI: 10.1177/24755303221099292.].
Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis

DOI: https://doi.org/10.1177/24755303231195869

Abstract:[This corrects the article DOI: 10.1177/2475530320950265.].
Erratum: She-Chuang-Si-Wu-Tang Alleviates Inflammation and Itching Symptoms in a Psoriasis Mouse Model by Regulating the Th17/IL-17 Axis via the STAT3/MAPK Pathways [Corrigendum]

DOI: https://doi.org/10.2147/JIR.S499600

2024-10-11

Abstract:[This corrects the article DOI: 10.2147/JIR.S472417.].
Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

DOI: https://doi.org/10.1177/24755303231195871

Abstract:[This corrects the article DOI: 10.1177/2475530320910466.].
Corrigendum: Alternative Splicing: a New Cause and Potential Therapeutic Target in Autoimmune Disease.

Pingping Ren,Luying Lu,Shasha Cai,Jianghua Chen,Weiqiang Lin,Fei Han

DOI: https://doi.org/10.3389/fimmu.2024.1513491

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.713540.].
Corrigendum to Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey

DOI: https://doi.org/10.1177/24755303231195870

Abstract:[This corrects the article DOI: 10.1177/2475530320956602.].
Erratum: Psoriasis comorbidity management in the COVID era: a pressing challenge

Frontiers Production Office

DOI: https://doi.org/10.3389/fmicb.2024.1502059

IF: 5.2

2024-10-08

Frontiers in Microbiology

Abstract:This article is an erratum on: Psoriasis comorbidity management in the COVID era: a pressing challenge

microbiology
Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

DOI: https://doi.org/10.1177/24755303231195883

Abstract:[This corrects the article DOI: 10.1177/24755303211037308.].

Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis

Corrigendum: IL36G is associated with cutaneous antiviral competence in psoriasis

Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab

Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series

Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

Corrigendum to “Exploring comorbidity and pharmacological treatment patterns in psoriasis - A retrospective population-based cross-sectional study”

Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

Corrigendum to Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey

Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis

Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series

Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities

Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes &amp; Diseases 9(2022) 443–455]

Corrigendum to Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options

Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis

Erratum: She-Chuang-Si-Wu-Tang Alleviates Inflammation and Itching Symptoms in a Psoriasis Mouse Model by Regulating the Th17/IL-17 Axis via the STAT3/MAPK Pathways [Corrigendum]

Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

Corrigendum: Alternative Splicing: a New Cause and Potential Therapeutic Target in Autoimmune Disease.

Corrigendum to Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey

Erratum: Psoriasis comorbidity management in the COVID era: a pressing challenge

Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes & Diseases 9(2022) 443–455]